Thrivent Financial for Lutherans Buys 7,369 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Thrivent Financial for Lutherans raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 20.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 43,177 shares of the medical research company’s stock after acquiring an additional 7,369 shares during the period. Thrivent Financial for Lutherans’ holdings in IQVIA were worth $10,231,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Capital Performance Advisors LLP bought a new position in shares of IQVIA in the 3rd quarter valued at $27,000. Park Place Capital Corp acquired a new stake in shares of IQVIA during the third quarter valued at about $28,000. Versant Capital Management Inc grew its holdings in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares during the last quarter. Opal Wealth Advisors LLC bought a new position in IQVIA in the 2nd quarter valued at approximately $27,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in IQVIA during the 2nd quarter worth approximately $29,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Up 1.6 %

IQV opened at $197.57 on Friday. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The stock has a market capitalization of $35.86 billion, a price-to-earnings ratio of 25.93, a PEG ratio of 1.97 and a beta of 1.51. The business has a fifty day moving average price of $223.40 and a 200 day moving average price of $227.35. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 6.24 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Truist Financial lowered their price target on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating for the company in a report on Monday, November 4th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 5th. Barclays reduced their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Robert W. Baird cut their price objective on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a research report on Friday, November 1st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a research report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.